Revenue
2022
2023
2024
2025
Immunome Inc. (IMNM)
Price$23.65Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | $0 | — | — | — |
| Research & development | $177.3M | $129.5M | $23.1M | $23.3M | $14.1M | $7.5M | $8.8M |
| Operating expenses | $231.1M | $314.8M | $123.5M | $36.9M | $25.2M | $12.3M | $10.3M |
| Operating income | −$224.1M | −$305.8M | −$109.5M | −$36.9M | −$25.2M | −$12.3M | −$10.3M |
| Operating margin | −3,228.83% | −3,382.37% | −781.35% | — | — | — | — |
| EBITDA | −$221.6M | −$304.2M | −$109.1M | −$36.5M | −$24.4M | −$11.5M | −$9.7M |
| EBITDA margin | −3,193.30% | −3,365.04% | −778.09% | — | — | — | — |
| Net income | −$212.4M | −$293.0M | −$106.8M | −$36.9M | −$24.7M | −$17.8M | −$10.4M |
| Net profit margin | −3,059.99% | −3,240.38% | −761.92% | — | — | — | — |
| Basic EPSper basic share | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | -$9.55 |
| Diluted EPSper diluted share | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | -$9.55 |
Owners
Reported shareholders
17.35%of listed shares
T. Rowe Price Investment Management, Inc.19.68M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
T. Rowe Price Investment Management, Inc. | 17.35%19.68M shares |
FMR LLC | 14.98%16.99M shares |
BlackRock, Inc. | 7.77%8.81M shares |
STATE STREET CORP | 4.85%5.49M shares |
WELLINGTON MANAGEMENT GROUP LLP | 4.59%5.21M shares |
Redmile Group, LLC | 4.33%4.91M shares |
PRIMECAP MANAGEMENT CO/CA/ | 4.04%4.58M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.01%4.55M shares |
Driehaus Capital Management LLC | 3.83%4.35M shares |
ENAVATE SCIENCES GP, LLC | 3.19%3.61M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.43%2.75M shares |
MORGAN STANLEY | 2.12%2.41M shares |
Barchas Isaac | ≈1.87%2.12M shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 1.78%2.02M shares |
JPMORGAN CHASE & CO | 1.63%1.85M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.56%1.77M shares |
Sofinnova Investments, Inc. | 1.52%1.72M shares |
READYSTATE ASSET MANAGEMENT LP | 1.42%1.61M shares |
GOLDMAN SACHS GROUP INC | 1.33%1.51M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.19%1.35M shares |
Percentages use 113.4M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Lechleider RobertChief Medical Officer | SellCommon Stock | 14.4K | $20.66 | $297.9K | 15.8K |
| Jun 25, 2026Form 4 · 10b5-1 | Lechleider RobertChief Medical Officer | SellCommon Stock | 40.6K | $19.56 | $793.7K | 30.2K |
| Jun 15, 2026Form 4 · 10b5-1 | Rosett MaxChief Financial Officer | SellCommon Stock | 60.0K | $18.23 | $1.09M | 54.0K |
| Jun 5, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyCommon Stock | 1.0K | $19.27 | $19.3K | 43.4K |
| Jun 5, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyCommon Stock | 3.5K | $19.46 | $68.1K | 42.4K |